

Cancer
Stem Cells
Cancer
Stemness
Inhibitor
Heterogeneous Cancer Cells

Fig.1



Cancer stem cell
specific therapy
Tumor
regression
S
Convertional
cancer therapy
Tumor relapse

Fig.2



Abl
KDR
EGFR
JAKs
c-Met
Src
Her2
Stat3
Bcl-xl、c-Myc、 cyclin D1 、Vegf、MMP-2、and survivin
Cancer Cells Proliferation
Apoptosis Resistance
Metastasis Angiogensis
Immune Tolerance

Fig.3



500
450
400
350
300
250
200
150
100
50
0
0
1
5
8
12
15
18
22
Control
GB201, 100mg/kg bid po
GEMZAR, 80mg/kg ip
GB201/Gemzar

Fig.4



control
2-acetylnaphtho[2,3-b] furan-4,9-dione
paclitaxel
2-acetylnaphtho[2,3-b] furan-4,9-dione + paclitaxel
P-Stat3
β-CATENIN
merge

Fig.5